Pharmaron Beijing Co., Ltd. Class H (DE:17Q1)
FRANKFURT:17Q1
17Q1 Stock Chart & Stats
€2.56
-€0.04(-2.45%)
At close: 4:00 PM EST
€2.56
-€0.04(-2.45%)
Day’s Range― - ―
52-Week Range€1.37 - €3.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.45B
Enterprise Value€48.36B
Total Cash (Recent Filing)€1.73B
Total Debt (Recent Filing)€3.42B
Price to Earnings (P/E)18.6
Beta0.77
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding359,977,870
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.69
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.32Price Target Upside29.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.14
Revenue Forecast (FY)€2.04B
Bulls Say, Bears Say
Bulls Say
Integrated R&D-to-manufacturing ModelPharmaron's end-to-end service platform (discovery, preclinical/clinical development, CDMO) creates durable client stickiness and cross-sell opportunities. Long-term contracts and multi-stage engagements raise lifetime value, diversify revenue sources and reduce single-project cyclicality.
Materially Stronger Balance SheetSharp decline in leverage materially lowers financial risk and interest burden, improving resilience to downturns. A stronger balance sheet supports strategic reinvestment, capacity expansion or selective M&A without forcing dilutive financing, enhancing long-term operational flexibility.
Consistent Positive Operating Cash FlowSustained positive operating cash flow indicates earnings quality and the business's ability to generate internal funds for working capital and reinvestment. Over time this supports capacity buildout and service delivery without excessive reliance on external financing.
Bears Say
Slowing Revenue GrowthA marked deceleration in top-line growth reduces operating leverage and future earnings upside. If the trend persists it may signal increased competition or weaker demand for services, constraining long-term margin expansion and the firm's ability to scale higher-margin offerings.
Margin Compression From Prior PeaksDeclining margins erode cash generation and the buffer against cost shocks. Sustained compression implies pricing pressure or higher operating costs; without structural shifts to higher-value services or efficiency gains, profitability and returns on invested capital may remain constrained.
Volatile And Modest Free Cash FlowInconsistent free cash flow limits capital allocation flexibility for dividends, buybacks or growth capex. The volatility suggests reinvestment intensity or working-capital swings; over the medium term this can force conservative investment or reliance on external funding for strategic initiatives.
Pharmaron Beijing Co., Ltd. Class H News
17Q1 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was €1.37 and its highest was €3.24 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is €6.45B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Apr 23, 2026 which is in 12 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported €0.036 earnings per share for the quarter, beating the consensus estimate of €0.034 by €0.002.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H does not currently pay dividends.
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of €0.036 in its last earnings report, beating expectations of €0.034. Following the earnings report the stock price went down -1%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:17Q1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
11.48%
Trailing 12-Months
Asset Growth
4.32%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
17Q1 Stock 12 Month Forecast
Average Price Target
€3.32
▲(29.49% Upside)
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---